Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're at the ASCO Annual Meeting, and I'm joined by Dr. Kohei Shitara. Thanks so much for coming on today. Dr. Shitara: My pleasure. Oncology Data Advisor: Would you like to introduce yourself and share what your work focuses on? Dr. Shitara: At this ASCO, I'm presenting two posters. One is the prevalence data of claudin 18.2 (CLDN18.2) in gastric cancer patients during two phase 3 trials, and the second is a trial in progress, a ph...

Oncology Data Advisor holds the utmost value for patient advocates and advocacy groups as they strive to prioritize patient-centered care and shared decision making throughout the cancer journey. At this year's American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor spoke with numerous individuals representing diverse aspects of oncology and asked them how they strive to partner with patients in their practice, research, and advocacy work.   Allison Rosen, Patient...

Oncology Data Advisor® · Groundbreaking Results of Mirvetuximab Soravtansine for Ovarian Cancer With Kathleen Moore, MD Welcome to Oncology Data Advisor, a digital resource for the multidisciplinary cancer team. At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Kathleen Moore, MD, Associate Director of Clinical Research and Professor of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma, sat down to discuss in detail her present...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Nicholas Philips. Thanks so much for joining me today. Nicholas Phillips, MD: Nice to meet you, and nice to be here. My name is Nick Philips. I'm a Physician Scientist at St. Jude Children's Research Hospital in the Department of Epidemiology and Cancer Control, and I'm here at ASCO to present my poster. Oncology Data Advisor: Yes, your poster here is on accelerated brain ...

Oncology Data Advisor® · Final Overall Survival Results of the CLEAR Study in Renal Cell Carcinoma With Thomas Hutson, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Thomas Hutson, Director of the Urologic Oncology Cancer Research and Treatment Center at Baylor Sammons Cancer Center, discusses the results of the CLEAR study, in which he and his co-investigators measured the safety and efficacy of lenvatinib plus pembrolizumab for treatment of advance...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Puneeth Indurlal. Thanks so much for coming on today. Puneeth Indurlal, MD: Thank you for having me. Oncology Data Advisor: Would you like to introduce yourself and share what your work and your research focus on? Dr. Indurlal: My name is Dr. Puneeth Indurlal. I'm a Senior Director for Care Transformation at the US Oncology Network. We've been focusing a lot on value-based...

Nicholas Robert, MD: My name is Nicholas Robert, the Chief Medical Officer for Ontada. Ontada is a McKesson company that's involved with data analytics in technology in the oncology space. Oncology Data Advisor: Today, we're talking about your study here at ASCO on social determinants of health. Would you like to tell us about the study? Dr. Robert: A little bit more than a year ago, Ontada decided that we wanted to give our physicians and our network, the US Oncology Network, the ability to do ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Michael Halpern. Thanks so much for coming on today. Michael Halpern, MD: Thank you for inviting me. Oncology Data Advisor: Would you like to introduce yourself and share what your work and your research focus on? Dr. Halpern: Sure, my name is Michael Halpern. I'm a Medical Officer at the National Cancer Institute (NCI) in the Healthcare Delivery Research Program, which is...

Oncology Data Advisor® · Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Noelle Cloven, a Gynecologic Oncologist at the Sarah Cannon Research Institute at Texas Oncology, sat down with Oncology Data Advisor to further discuss her presentation this year encompassing the ongoing ARTISTRY-7 trial. This trial seeks to evaluate the safety and efficacy of nemvaleukin al...

Oncology Data Advisor® · Improving Outcomes for IDH1/2-Mutant Glioma in the INDIGO Study With Timothy Cloughesy, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Timothy Cloughesy, Director of the Neuro-Oncology Program at the University of California Los Angeles (UCLA), sat down to further discuss his presentation regarding the INDIGO study, of which he is the senior author. The INDIGO study seeks to understand the safety and efficacy of vorasidenib for t...

Oncology Data Advisor® · mCSPC: Real World Characteristics and Treatment by Disease Volume With Stephen Freedland, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, sat down with Oncology Data Advisor to discuss his abstract regarding real-world characteristics and treatment by disease volume among patients with metastatic castration-sensitive prostate cancer. Dr. Freedland shares m...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Stephanie Smith. Thank you so much for coming on today. Stephanie Smith, MD: Thanks for the invite. Oncology Data Advisor: Would you like to introduce yourself and share what your work focuses on? Dr. Smith: Absolutely. My name is Stephanie Smith. I'm a Pediatric Oncologist and Cancer Survivorship Researcher at Stanford. My research focuses on the intersections between onc...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Stephen Freedland. Thanks for coming on today. Stephen Freedland, MD: Hello, absolutely. Thanks for having me. Oncology Data Advisor: Would you like to introduce yourself and share what your work and your research focus on? Dr. Freedland: Yes, I'm Steve Freedland. I'm a urologist—a little bit of out of place here at ASCO, but it's fun to be here. I'm at Cedars-Sinai Medica...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Richard Newcomb. Thanks much for coming on. Richard Newcomb, MD: Yes, thanks for having me. Oncology Data Advisor: You're presenting a poster here about uncertainty and coping in patients with newly diagnosed indolent non-Hodgkin's lymphoma. To start off, could you tell us a little bit about indolent NHL and why you chose to study this patient population? Dr. Newcomb: As b...

Oncology Data Advisor® · Payment Reform Through the Enhancing Oncology Model With Lalan Wilfong, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down for a conversation with Dr. Lalan Wilfong, the Senior Vice President of Payer and Care Transformation for the US Oncology Network, to discuss his presentation concerning payment reform and lessons learned from the Oncology Care Model (OCM) and the Enhancing Oncology Model...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Janet Espirito. Thank you so much for joining me today. Janet Espirito, PharmD: Thank you for having me. Oncology Data Advisor: So, you have an abstract here titled Real-World Response End Points in Patients With Metastatic NSCLC Treated With Chemotherapy Across Real-World Data Sets. What was the background of this study, and why did you decide to investigate this? Dr. Espirit...

Oncology Data Advisor® · Coaching Cancer Survivors Through Digital Health: Robin Lally, PhD, and Marilyn Hammer, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down for a conversation with Robin Lally, PhD, and Marilyn Hammer, PhD, co–Principal Investigators of the COACH (Comprehensive Outcomes for After-Cancer Health) study. Dr. Lally and Dr. Hammer share the background of this study and how it is seeking to improve...

Oncology Data Advisor: Today, we're at the ASCO Annual Meeting, and I'm joined by Robin Lally and Marilyn Hammer. Thank you both so much for coming on today. Robin Lally, PhD: Thank you, it's very nice to be here. Oncology Data Advisor: Would you like to introduce yourselves and share what your work and your research focus on? Dr. Lally: Sure, I'm Dr. Robin Lally. I'm a Professor in the College of Nursing at the University of Nebraska Medical Center's Fred & Pamela Buffett Cancer Center. My ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Mandy Pratt-Chapman. Thanks so much for coming on today. Mandi Pratt-Chapman, PhD: Absolutely. Oncology Data Advisor: Would you like to introduce yourself and share a little bit about what your work and your research focus on? Dr. Pratt-Chapman: I am an Associate Professor of Medicine at the George Washington University Cancer Center and School of Medicine. I am Associate Cent...

Oncology Data Advisor® · Molecular Analyses of Sacituzumab Govitecan in Urothelial Carcinoma With Manoj Bupathi, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Manojkumar Bupathi, MD, MS, a Genitourinary (GU) Medical Oncologist at Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, to talk about his two studies he is presenting this year about the efficacy and safety of sacituzumab govitecan (SG) in urothe...

Oncology Data Advisor® · Reducing Cost of Cancer Care Through Novel Therapy Adjustment With Erica Feinberg, PharmD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Erica Feinberg, PharmD, BCPS, a Senior Clinical Data Analyst at The US Oncology Network, to discuss her poster regarding novel therapy adjustments to the Enhancing Oncology Model (EOM) and the Oncology Care Model (OCM).   Oncology Data Advisor: Welcome ...

Oncology Data Advisor® · Partnering With Patients Through Advocacy With Allison Rosen At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Allison Rosen, a colorectal cancer survivor, patient advocate, and Director of Project ECHO for the American Cancer Society. Ms. Rosen shares the story of her cancer journey, how she became involved in patient advocacy, and how she strives to use her platform to bridge the gap between cli...

Oncology Data Advisor: Thanks so much for coming on today. Allison Rosen, MS: Of course. Happy to be here. Oncology Data Advisor: Would you like to introduce yourself and share a little bit about your story and how you became involved in patient advocacy? Oncology Data Advisor: Sure. I'm a 10-year colorectal cancer survivor. Ten years ago, I was working in cancer research and living life to the fullest—working out, going out, having a great time. I started having interesting symptoms that I had ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Pant. Thank you so much for joining. Shubham Pant, MD: Thank you. Oncology Data Advisor: I'm interested to hear more about the results of the HERIZON-BTC-01 trial that you are presenting. Would you like to give us an overview and some background about this trial? Dr. Pant: Yes, so this was a global phase 2b trial done in HER2-positive patients with biliary tract cancers. I...

Oncology Data Advisor® · Trastuzumab Deruxtecan Safety on HER2 Expressing Solid Tumors With Funda Meric-Bernstam, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Funda Meric-Bernstam, the Department Chair in the Department of Vascular Cancer Therapeutics at MD Anderson Cancer Center, sat down with Oncology Data Advisor to discuss her presentation of the results of the Destiny-PanTumor-02 trial, in which her team studied the safety of trastuzumab ...

Oncology Data Advisor® · Exciting New Directions for Oncology Data Advisor: Live From ASCO 2023 With Dr.Thomas Abrams At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Thomas Abrams, Editor in Chief of Oncology Data Advisor, previewed some of the latest updates on Oncology Data Advisor and the new directions that will be taken in 2023, including new ways of partnering with patients to strengthen the patient voice and ultimately improve quality of ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting in Chicago, and I'm joined by Dr. Tom Abrams, who is our Editor in Chief. Thomas Abrams, MD: I'm so happy to be here. It's been a great meeting, and I'm just happy to get in front of the camera here and do a podcast. Oncology Data Advisor: Yes, definitely. How are you enjoying your time at ASCO so far? Dr. Abrams: It's been great. It's a whirlwind of a meeting, but you get to reconnect with a lo...

Coaching Cancer Survivors Through Digital Health With Robin Lally, PhD, and Marilyn Hammer, PhDExciting New Directions for Oncology Data Advisor With Thomas Abrams, MD, Editor in ChiefPickles Group: Supporting Kids Impacted by Parental Cancer With Cassy HortonExploring Primary Overall Survival Results of Axicabtagene Ciloleucel in the ZUMA-7 Trial With Jason Westin, MDHemePath Hub: A Unique Learning Opportunity for Hematologic Cancers With Aamir Ehsan, MD, and Bridget Herschap, MD, of CorePath L...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Darya Kizub. Thank you so much for coming on today. Darya Kizub, MD: Thank you for inviting me. Oncology Data Advisor: So, you're about to present your poster about connecting Black families in Houston, Texas, to hereditary cancer genetic counseling and testing. Would you like to give a little bit of background about why you decided to investigate this? Dr. Kizub: Yes. So,...

Oncology Data Advisor® · Expanding Global Health Education Through Video and Social Media With Yan Leyfman, MD At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor sat down with Dr. Yan Leyfman, a physician at Mount Sinai Hospital and Director and Host of MedNews Week. Dr. Leyfman explains the origin and reach of MedNews Week and how it strives to combat health care information, champion patient advocacy, and expand global health ed...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Yan Leyfman. Thanks so much for coming on today. Yan Leyfman, MD: Thank you so much for having me. It's truly a pleasure to be here. Oncology Data Advisor: Would you like to introduce yourself and your platform, MedNews Week? Dr. Leyfman: Sure, thank you so much for the opportunity. I am a physician and a researcher from Mount Sinai, New York. During the height of the COVI...

Oncology Data Advisor® · Renal Cell Carcinoma Research and Shared Decision Making With Bradley McGregor, MD At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor® sat down with Bradley McGregor, MD, Director of Clinical Research for the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute, to discuss his presentation regarding the results of the phase 2 study of cabozantinib (cabo) with nivolumab (nivo) an...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Jason Westin. Thank you so much for coming on today. Jason Westin, MD: I'm happy to be here. Thanks for having me. Oncology Data Advisor: Would you like to introduce yourself and share what your work focuses on? Dr. Westin: Of course. I'm Dr. Jason Westin from MD Anderson Cancer Center in Houston, Texas. I'm the Director of Lymphoma Clinical Research and the Section Chief ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Dr. Deepa Rangachari. Thanks so much for coming on today. Deepa Rangachari, MD: Keira, thanks so much for the invitation. Again, my name is Deepa Rangachari. I am the Director of Hematology/Oncology (Heme/Onc) Graduate Medical Education and the Hematology/Oncology Fellowship Program at the Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts. I'm really deligh...

Oncology Data Advisor® · Social Media’s Effect on Informed Decision Making in Cancer Treatment Welcome to Oncology Data Advisor®, a digital resource for the multidisciplinary cancer team. In this podcast episode, Nina Morena, MA, PhD Candidate at McGill University, and Ari Meguerditchian, MD, Surgical Oncologist at McGill University Health Center, sit down to talk about Ms. Morena's thesis topic and research, How reliable are post-mastectomy breast reconstruction videos on YouTu...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual meeting, and I'm joined by Dr. Aamir Ehsan and Dr. Bridget Herschap from CorePath Laboratories. Thank you both so much for coming on today. Would like to introduce yourselves and share what you do at CorePath? Aamir Ehsan, MD: This is Dr. Aamir Ehsan. I'm the CEO and Medical Director of CorePath Laboratories in San Antonio, Texas. Bridget Herschap, MD: This is Dr. Bridget Herschap. I'm the Medical Direc...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today we're here at the ASCO Annual Meeting, and I'm joined by Cassy Horton. Thanks so much for coming on today. Cassy Horton: I'm very happy to be here. Oncology Data Advisor: Would you like to introduce yourself and share how you became involved with Pickles Group? Cassy Horton: Sure. So my name's Cassy Horton. I'm the Executive Director of Pickles Group. I come from a nonprofit and youth services background, so I've really built a caree...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're here at the ASCO Annual Meeting, and I'm joined by Barb Kunz. Thanks so much for coming on today. Barb Kunz: Thanks for having us. Oncology Data Advisor: Would you like to introduce yourself and share what your work and your research focus on? Ms. Kunz: My name is Barb Kunz, and I'm a genetic counselor with the US Oncology Network. I was part of a study that Ontada sponsored, that six of our practices that have genetics progra...

Oncology Data Advisor® · Live Podcasts From the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Oncology Data Advisor™ · Increasing Medical Student Confidence When Treating LGBTQIA+ Patients Following the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Cherry Au, MD, of Rush University Medical Center, spoke with Oncology Data Advisor to discuss her abstract, Medical Student Clinical Cultural Awareness in Cancer Care of Sexual and Gender Minorities. Oncology Data Advisor: Welcome to Oncology Data Advisor, I am Lyn Brook. Today I am joined by Cherr...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Urvi Shah from Memorial Sloan Kettering Cancer Center (MSKCC). Thank you for joining us. Would you like to tell us a little bit about yourself? Urvi Shah, MD: Sure. I'm a Hematologist and Oncologist on the Myeloma Service at Memorial Sloan Kettering Cancer Center. I'm happy to be here to talk to you all. Oncology Data: I know you moderated the poster disc...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Karen Basen-Engquist at the ASCO 2022 Meeting, where she was part of a very interesting session, a practical toolkit to getting your patients moving and why it matters. Dr. Basen-Engquist, what benefits does exercise have for patients with cancer? Karen Basen-Engquist, PhD, MPH: Oh, exercise is tremendously beneficial for patients with cancer. We have randomized trials that have demonstrated that exercise helps remediate...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Ash Alpert. Thank you so much for joining us. Ash Alpert, MD, MFA: I'm Dr. Ash Alpert. I'm a postdoctoral fellow in health services research at Brown University, and I'm a hematologist and medical oncologist. My research focuses on improving the experiences and outcomes of transgender people with cancer. Oncology Data Advisor: Would you like to tell us a little bit about the two posters that you presented at ASCO re...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Colin Ferro from Epic Experience. Thank you so much for joining us. Mr. Ferro: Thank you for having me.  Our mission is to empower adult cancer survivors and thrivers beyond their cancer diagnosis." by Author Oncology Data Advisor: Would you like to tell us a little bit about Epic Experience and what you do? Mr. Ferro: So, Epic Experience is a nonpro...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Ian Krop of Yale University who presented data on the novel HER3-targeting antibody-drug conjugate patritumab deruxtecan in HER3-expressing metastatic breast cancer. Thank you for joining us, Dr. Krop. Ian Krop, MD, PhD: I'm happy to be here. And just so you know, we all call it just HER3-DXd, which is a lot easier to say than patritumab deruxtecan. Oncology Data Advisor: Thank you. Why is there so much excitement about ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Dr. Jeannie Tie from the Peter MacCallum Cancer Centre at the University of Melbourne and Walter and Eliza Hall Institute. She presented the results of the randomized DYNAMIC trial on adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer. This work was also just published in the New England Journal of Medicine. Thank you for joining us, Dr. Tie. Jeanne Tie, MD, MBChB, FRACP: You're welcome. ...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here at the ASCO Annual Meeting in Chicago speaking with Jessica Jones of the UT Health System. Thank you so much for joining us here. Jessica Jones, MD: Thank you for having me. Oncology Data Advisor: Yes, absolutely. So you've done a lot of work and research in breast cancer prevention, especially for Black American women. Would you like to tell us about that? Dr. Jones: Yes. Thank you for asking. So I'd like t...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm here with Dr. Alexander Spira, Director of the Thoracic and Phase I Program for the Virginia Cancer Specialists, the US Oncology Network. He just presented his research as part of the oral abstract session on non–small cell lung cancer at the ASCO 2022 Annual Meeting, and it is also being published in today's New England Journal of Medicine. Dr. Spira, would you like to comment on the significance of these results of adagrasib for KRAS...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago speaking with Jason Mouabbi from MD Anderson Cancer Center. Thank you so much for joining us today. Jason Mouabbi, MD: Thank you, happy to be here. Oncology Data Advisor: Would you like to tell us a little bit about your poster here? Dr. Mouabbi: Yes, sure. At MD Anderson, I'm responsible for lobular breast cancer. I'm an expert in that field. Recently, we have shown in...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I am Lyn Brook. Today I am joined by Cherry Au, Resident Physician at Rush University Medical Center. Recently at ASCO, she presented her abstract about medical student readiness for treating sexual and gender minority patients with confidence and comfortability. Would you like to begin with introducing yourself and telling us a bit about your interests and what you study? Cherry Au, MD: Yeah. My name is Cherry Au. I'm currently a Postgrad...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Megan-Claire Chase of SHARE Cancer Support. Megan-Claire, thank you so much for being with us today. Megan-Claire Chase: Thank you so much. I'm so excited. Oncology Data Advisor: So, would you like to tell us a little bit about your story? Ms. Chase: Yes. So, my story begins like this; I always knew I would get cancer, and that's not because I'm a pessimi...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Urvi Shah from Memorial Sloan Kettering Cancer Center (MSKCC). Thank you for joining us. Would you like to tell us a little bit about yourself? Urvi Shah, MD: Sure. I'm a Hematologist and Oncologist on the Myeloma Service at Memorial Sloan Kettering Cancer Center. I'm happy to be here to talk to you all. Oncology Data: I know you moderated the poster disc...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Beth Heller and I'm at the ASCO 2022 Annual Meeting with Dr. Gombos. How are you today? And what are you doing at ASCO? Dan Gombos, MD, FACS: I'm doing great. ASCO is really the preeminent meeting for people who practice medical oncology. My world is a little bit different because I'm an ocular oncologist. Oncology Data Advisor: You are the first ocular oncologist I've ever met. Dr. Gombos: Well, ocular oncology is a very small, subspe...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, and I'm speaking with Kathi Mooney from Huntsman Cancer Institute. Thank you so much for joining us. Would you like to tell us a little bit about what you do? Kathi Mooney, PhD, RN, FAAN: Yes. Thank you for having me. I am Kathi Mooney, and I am from the University of Utah where the Huntsman Cancer Institute is, and I am here presenting two pieces of our research that ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I am here with Mark T. Fleming, a Medical Oncologist from the Virginia Oncology Associates, the US Oncology Network, who is at the ASCO 2022 Annual Meeting to present his work on the impact of diversity, equity, and inclusion training in an independent community oncology practice. Thank you for joining us, Dr. Fleming. Mark Fleming, MD: Thank you for having me. Oncology Data Advisor: Thanks. What is the importance of including diversity, e...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here at the ASCO Annual Meeting in Chicago speaking with Leif Honda and Jon Wetzel from TriMetis Life Sciences. Thank you for joining us here. Leif Honda: Thank you, Keira. It's good to be here. Oncology Data Advisor: Would you like to introduce yourselves? Jon Wetzel: Hi, I'm Jon Wetzel and I'm the COO here of TriMetis. We want to use those tools to help us when we're talking about the development of therapeutic...

Navdeep Dehar, MD, MBT, CCRP: My name is Navdeep Dehar and I am from Queen's University. I am a Medical Oncology Fellow there, and I am here to learn. This is my first ASCO. Oncology Data Advisor: Awesome. So, what are some of the most exciting things that you've seen here at ASCO so far? It's always important to see the person who you are giving the treatments to, not the disease you are treating by Author Dr. Dehar: I have attended the Presidential Address, which was exciting. I also heard dif...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Dr. Sam Kareff from the University of Miami. Thank you so much for joining us today. Sam Kareff, MD, MPH: Thanks for having me. Oncology Data Advisor: So, would you like to tell us about your poster that you presented here? Dr. Kareff: Sure. So, for our group, in conjunction at the University of Miami and the Caris Precision Oncology Alliance, I presented...

Oncology Data Advisor: Would you like to introduce and tell us a bit about yourself? Nick Dionne-Odom, PhD, RN: My name is Nick Dionne-Odom. I'm an Assistant Professor in the School of Nursing at the University of Alabama at Birmingham. Oncology Data Advisor: Would you like to give us an overview of the bias experienced by caregivers regarding cancer-related decisions? Dr. Dionne-Odom: Sure. I partnered with a 401(c)3 called Cancer Care, which is based in New York, to conduct a large national su...

Oncology Data Advisor™ · Medical Student Readiness to Treat LGBTQIA+ Patients: Matthew Schabath, PhD At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Matt Schabath, Associate Researcher at Moffitt Cancer Center, met with Oncology Data Advisor to discuss medical student readiness and confidence when treating LGBTQIA+ patients. This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. Oncolog...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Danet Peterson. Danet, thank you for joining us. Would you like to tell us a little bit about yourself? Danet Peterson: Sure. I am here from Phoenix, Arizona, and I'm here with the organization A Cure in Sight. We are a nonprofit for patients, created by patients, with ocular melanoma. I was actually diagnosed with ocular melanoma myself in July of 2020. ...

Oncology Data Advisor: Would you like to introduce yourself and give us an overview of your presentations this year at ASCO? Debra Patt, MD, PhD, MBA, FASCO: My name is Dr. Debra Patt. I serve as an Executive Vice President of Texas Oncology, part of the US Oncology Network. And I'm excited, at ASCO, to present information on our digital health solutions. One of the first studies that we presented looks at characteristics of utilization among different patient populations with our digital health...

Oncology Data Advisor: Hello, I'm Beth Heller, and I'm here today with Oncology Data Advisor at ASCO 2022. Stephanie Van Winkle: I'm Stephanie Van Winkle, and I'm Executive Director of Oncology State Societies at the Association for Community Cancer Centers. Oncology Data Advisor: What are you doing here at ASCO? Stephanie Van Winkle: My organization manages 21 of the state oncology societies across the country, and we are part of the state affiliate program of ASCO. So if you walk into the exhi...

Oncology Data Advisor™ · The Nurse's Role in Oncology Research and Quality Care: Jeannine Brant, PhD, APRN At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Jeannine Brant, PhD, APRN, President of the Oncology Nursing Society (ONS), sat down with Oncology Data Advisor to talk about the exciting research being presented by nurses at ASCO and the critical role of nurses in delivering quality oncology care. This podcast episode was recorded live at t...

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Beth Koselke, PharmD, BCOP, of the US Oncology Network, presented her team's research regarding the impact of a clinical pharmacist intervention program in oncology trial enrollment. Afterwards, she spoke with Oncology Data Advisor to explain the significance of the study's results and to further enlighten us about the role that pharmacists can play in clinical trial design, screening, and enrollment. Oncology ...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today, I'm here at the ASCO Annual Meeting in Chicago, speaking with Beth Peck from Project Koru. Thank you so much for joining us here. Beth Peck: Thanks for having me. Oncology Data Advisor: Tell us about Project Koru. What do you do? Ms. Peck: Project Koru is really in the realm of survivorship. We serve young adult cancer survivors who are between the ages 19 to 39, once they're done with their treatment and they've go...

Oncology Data Advisor: Welcome to Oncology Data Advisor, I'm Keira Smith. Today I'm here at the ASCO Annual Meeting in Chicago, speaking with David Penberthy of the Association of Community Cancer Centers. Thank you for joining us. Would you like to tell us a little bit about what you do there? David Penberthy, MD, MBA: Sure, thank you for having me. I'm really excited to be here at ASCO 2022. My name is David Penberthy. I'm a radiation oncologist in practice in the southern part of Virginia. I'...

Oncology Data Advisor: Welcome to Oncology Data Advisor. I'm Keira Smith. Today I'm at the ASCO Annual Meeting in Chicago, speaking with Dr. Aamir Ehsan, who is President of CorePath Laboratories. Thank you for joining us. Aamir Ehsan, MD: You're welcome. Oncology Data Advisor: So, would you like to tell us a little bit about personalized and precise diagnosis of cancer by pathology? Dr. Ehsan: Yes, sure. Thank you for the opportunity. My name, as you said, is Aamir Ehsan, representing a Clinica...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm joined by Dr. Deb Lundquist, Clinical Research Nurse from Massachusetts General Hospital. Recently, she provided a presentation at the 2022 ASCO Annual Meeting titled Patient-Reported Hope, Quality of Life, Symptom Burden, and Coping Mechanisms in Early Phase Clinical Trial Participants. Would you like to introduce yourself, what you do, and some things you are interested in? Debra Lundquist, PhD, RN: Sure. My name is Deb Lundqui...

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, Dr. Melissa Hudson of St. Jude Research Hospital, spoke with Oncology Data Advisor about the phase II trial of dabrafenib/trametinib for BRAF V600–mutant pediatric low-grade glioma, which was presented at the meeting by Dr. Eric Bouffet of the University of Toronto's Hospital for Sick Children. Dr. Hudson provides commentary on the study's results and shares additional insights into her research regar...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm here with Dr. Ash Alpert. Thank you so much for joining us. Ash Alpert, MD, MFA: I'm Dr. Ash Alpert. I'm a postdoctoral fellow in health services research at Brown University, and I'm a hematologist and medical oncologist. My research focuses on improving the experiences and outcomes of transgender people with cancer. Oncology Data Advisor: Would you like to tell us a little bit about the two posters that you presented at ASCO re...

Oncology Data Advisor: Welcome to Oncology Data Advisor. Today I'm joined by Dr. Deb Lundquist, Clinical Research Nurse from Massachusetts General Hospital. Recently, she provided a presentation at the 2022 ASCO Annual Meeting titled Patient-Reported Hope, Quality of Life, Symptom Burden, and Coping Mechanisms in Early Phase Clinical Trial Participants. Would you like to introduce yourself, what you do, and some things you are interested in? Debra Lundquist, PhD, RN: Sure. My name is Deb Lundqui...